Biotron Limited Stock

BIT

AU000000BIT4

Biotechnology & Medical Research

Market Closed - Australian S.E. 23:34:33 2026-10-29 EDT			5-day change	1st Jan Change
0.002000 ^AUD	0.00%		0.00%	-33.33%

10-18	Biotron Limited Announces Appointment of Michael J. Thurn as Non-Executive Director, Effective October 19, 2026	CI
10-13	Biotron Limited Announces Appointment of Glenn Gilbert as Executive Director, Effective January 18, 2027	CI

Biotron Limited is a clinical-stage biotechnology company. The Company is engaged in developing and commercializing a novel small molecule approach that has the potential to treat several serious viral diseases. Its proprietary primary bacterial cell-based screening platform enables rapid screening for target viroporin proteins, including hepatitis C, HIV-1, Dengue, Zika, Influenza, and Respiratory Syncytial Virus (RSV). The Company has developed a library of over 350 compounds with potential activity against a range of viral diseases. Its lead compound, BIT225, is in Phase II development for the treatment of HIV-1. BIT225 appears to inhibit HIV-1 replication in macrophage reservoir cells offering the potential, when used in combination with other anti-retroviral compounds, to eradicate HIV-1. The Company also owns SedRx, which is a general anesthetic containing alfaxalone.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-10-30	A$0.002000	0.00%	2,503,271
26-10-27	A$0.002000	0.00%	290,498
26-10-26	A$0.002000	0.00%	674,485
26-10-23	A$0.002000	0.00%	288,800
26-10-22	A$0.002000	0.00%	1,519

Delayed Quote Australian S.E.

More quotes

As early as today, start finding the best investment opportunities!

Market Cap	5.57M 3.92M 3.51M 3.23M 2.93M 5.47M 372M 38.5M 15.46M 196M 14.71M 14.39M 617M	P/E 2025	-6.29x	P/E 2026	-4.1x
Enterprise Value	4.02M 2.83M 2.53M 2.33M 2.11M 3.94M 268M 27.76M 11.14M 141M 10.6M 10.38M 445M	EV / Sales 2025	0.95x	EV / Sales 2026	12.5x
Free-Float	64.35%	Yield 2025 *	-	Yield 2026	-

10-18	Biotron Limited Announces Appointment of Michael J. Thurn as Non-Executive Director, Effective October 19, 2026	CI
10-13	Biotron Limited Announces Appointment of Glenn Gilbert as Executive Director, Effective January 18, 2027	CI
10-13	Biotron Limited Announces Appointment of Glenn Gilbert as Chief Executive Officer, Effective January 18, 2027	CI
08-27	Biotron Limited Reports Earnings Results for the Full Year Ended June 30, 2026	CI
08-26	Biotron Limited Auditor Raises 'Going Concern' Doubt	CI
04-09	Biotron Michael Hoy to retire as chairman	RE
04-09	Biotron Limited Announces Chairman Changes	CI
03-30	Biotron Limited Appoints Graeme Wald as Non-Executive Director, Effective March 30, 2026	CI
02-26	Biotron Limited Reports Earnings Results for the Half Year Ended December 31, 2025	CI
02-05	Biotron Limited Announces Retirement of Robert B. Thomas as Non-Executive Director, Effective February 6, 2026	CI
12-28	New Zealand Shares End Lower Amid Silver Reaching Record Highs; Bankers Investment Trust Reports Net Asset Value	MT
12-22	Biotron Limited Appoints Paul Kasian as Non-Executive Director, Effective 23 December 2025	CI
25-10-14	Biotron to raise A$2.5 mln through 2 tranche placement at A$0.003 per share	RE

22-05-01	Biotron : BIT225 EFFECTIVE AGAINST ESTABLISHED SARS-CoV-2 IN ANIMALS	PU
21-11-24	BIOTRON : DRUG EFFECTIVE AGAINST COVID-19 IN ANIMALS	PU
21-11-22	Biotron : Chairman's Address and Presentation to AGM	PU
19-12-16	Biotron : 17 Dec 2019Exercise of Options Raise $5.8 Million & Appendix 2A	PU
19-12-04	Biotron : 5 Dec 2019Appendix 3Y – Change of Director’s Interest Notice	PU

6 months	-20.00%
Current year	-33.33%

1 week	0		0
1 month	0		0
Current year	0		0
1 year	0		0
3 years	0		0.12
5 years	0		0.12
10 years	0		0.44

Biotron Limited Stock

Stocks

BIT

AU000000BIT4

Biotechnology & Medical Research

Valuation: Biotron Limited

Chart: Biotron Limited

Latest news: Biotron Limited

Press Releases: Biotron Limited

Quotes and Performance

Price Extremes

Managers and Directors: Biotron Limited

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Director	Title	Age	Since
Michael Medway BRD	Director/Board Member	-	2025-07-15
Paul Kasian CHM	Chairman	68	2026-05-30
Graeme Wald BRD	Director/Board Member	63	2026-03-29

Date	Insider	Type	Main position	Quantity	% Market Cap.
11/28/24	Michelle Miller	Expiration	Chief Executive Officer	165,000	0.0183%
11/28/24	Robert Thomas	Expiration	Director	268,403	0.0297%
11/28/24	Michael Hoy	Expiration	Chairman	934,780	0.1036%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BIOTRON LIMITED	0.00%	0.00%	-50.00%	-97.87%	3.92M
WUXI APPTEC CO., LTD.	-0.62%	-1.87%	+46.31%	+56.99%	63.77B
ARGENX SE	+0.35%	+3.20%	+14.92%	+84.55%	56.37B
LONZA GROUP AG	+0.53%	+1.96%	+15.37%	+106.81%	54.62B
IQVIA HOLDINGS INC.	-2.81%	-4.31%	+23.50%	+50.90%	44.06B
BEONE MEDICINES AG	-0.33%	-1.93%	+20.15%	+98.45%	42.11B
REVOLUTION MEDICINES, INC.	+0.55%	+2.31%	+224.97%	+942.56%	41B
GENMAB A/S	+3.27%	+47.96%	+112.67%	+96.48%	34.92B
CELLTRION, INC.	+1.22%	-1.44%	+14.89%	+47.15%	32.82B
INSMED INCORPORATED	+0.89%	+20.55%	-42.03%	+373.03%	24.7B
Average	+0.31%	+6.79%	+38.07%	+175.90%	39.43B
Weighted average by Cap.	+0.18%	+5.44%	+48.50%	+186.13%

	2025	2026
Net sales	1.81M 1.28M 1.14M 1.05M 952K 1.78M 121M 12.53M 5.03M 63.73M 4.79M 4.69M 201M	526K 370K 331K 305K 276K 516K 35.13M 3.63M 1.46M 18.48M 1.39M 1.36M 58.27M
Net income	-319K -224K -201K -185K -167K -313K -21.28M -2.2M -884K -11.19M -841K -823K -35.3M	-1.52M -1.07M -957K -880K -797K -1.49M -101M -10.49M -4.21M -53.35M -4.01M -3.92M -168M
Net Debt	-932K -655K -587K -540K -489K -915K -62.24M -6.44M -2.58M -32.74M -2.46M -2.41M -103M	-1.55M -1.09M -979K -901K -816K -1.53M -104M -10.74M -4.31M -54.6M -4.1M -4.02M -172M

Markets		Quality
Australian S.E.	BIT	Delayed
OTC Markets	BITRF	Delayed